CERo Therapeutics

Executive Summary

CERo Therapeutics is a private cell therapy company based in South San Francisco, founded in 2018. The company's mission is to develop curative cell therapies that engineer T cells to incorporate multiple mechanisms of tumor clearance, such as chimeric antigen receptors (CARs) and T cell receptor (TCR) signaling, into a single cell. This dual targeting approach aims to overcome tumor heterogeneity and resistance. Currently in preclinical development, CERo's platform has not yet entered clinical trials, but its innovative strategy positions it within the competitive cell therapy landscape. The company is pre-revenue and has not disclosed funding or valuation. Its success depends on advancing its lead candidate into the clinic and demonstrating safety and efficacy in early-phase studies.

Upcoming Catalysts (preview)

• Q3 2026IND Submission for Lead Candidate50% success
• H1 2026Preclinical Data Presentation at Major Conference (e.g., ASGCT or SITC)70% success
• H2 2026Announcement of Strategic Partnership or Licensing Deal30% success